← All trials
NCT00531167
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2007
- Primary completion
- Apr 1, 2011
- Completion date
- Oct 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 219
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Korea UniversityLead sponsor
- Korea UniversityOverall official - principal investigator
- Korea UniversityStudy director
- Chungbuk National UniversityStudy director
- Yonsei UniversityStudy director
- Hallym UniversityStudy director
- Inha UniversityStudy director
- Genematrix Inc.Study director
- Gachon UniversityStudy director
- GlaxoSmithKlineCollaborator
- Korea UniversityReponsible party - principal investigator
- Catholic University of KoreaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.